BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receives NICE Recommendation as 1L Treatment of Malignant Pleural Mesothelioma
Shots:
- The NICE has issued a FAD recommending the use of BMS’ Opdivo + Yervoy on the NHS for the treatment of unresectable MPM in adult patients in England and Wales
- The clinical trials have shown that the combination is an improved option to CT for untreated mesothelioma with 8% more patients surviving the disease after 3yrs. and 13% more demonstrating that their cancer has stopped advancing during that time
- Nivolumab (q3w) and ipillmumab (q6w) will be administered to patients as IV in 30min. sessions for ~2yrs.
Ref: NHS England | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
